Appendix 3Y Change of Director's Interest Notice
Appendix 3Y
Rule 3.19A.2
For personal use only
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity ZELIRA THERAPEUTICS LIMITED
ABN | 27 103 782 378 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Harry Karelis |
Date of last notice | 17 November 2021 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest | Gemelli Nominees Pty Ltd |
(including registered holder) | A/C> - Director/shareholder |
Note: Provide details of the circumstances giving rise to the relevant | |
interest. | |
Date of change | 3 February 2022 |
No. of securities held prior to change | 49,587,680 ordinary shares |
6,250,000 Class A performance rights | |
6,250,000 Class B performance rights | |
Class | Fully paid ordinary shares |
Class A performance rights | |
Number acquired | 6,250,000 ordinary shares |
Number disposed | 6,250,000 Class A performance rights |
Value/Consideration | Pursuant to the satisfaction of the Class A |
Note: If consideration is non-cash, provide details and estimated | Performance Right milestone as announced on 10 |
valuation | January 2022 estimated value $0.028 per share. |
No. of securities held after change | 55,837,680 ordinary shares |
Nil Class A performance rights | |
6,250,000 Class B performance rights | |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Nature of change | Conversion of Class A Performance Rights |
Example: on-market trade, off-market trade, exercise of options, | pursuant to the satisfaction of the Class A |
issue of securities under dividend reinvestment plan, participation in | Performance Right milestone as announced on 10 |
buy-back | |
January 2022 | |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Part 3 - +Closed period
Were the interests in the securities or contracts detailed | No |
above traded during a +closed period where prior written | |
clearance was required? | |
If so, was prior written clearance provided to allow the trade | N/A |
to proceed during this period? | |
If prior written clearance was provided, on what date was this | N/A |
provided? |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3
Appendix 3Y Change of Director's Interest Notice
Appendix 3Y
Rule 3.19A.2
For personal use only
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity ZELIRA THERAPEUTICS LIMITED
ABN | 27 103 782 378 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Oludare Odumosu |
Date of last notice | 11 August 2020 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Direct | ||||||
Nature of indirect interest | |||||||
(including registered holder) | |||||||
Note: Provide details of the circumstances giving rise to the relevant | |||||||
interest. | |||||||
Date of change | 3 February 2022 | ||||||
No. of securities held prior to change | A. | 5,500,655 ordinary shares | |||||
B. | 17,558,328 Class A performance rights | ||||||
C. | 17,558,328 Class B performance rights | ||||||
D. | 5,000,000 | Unquoted | options exercisable | ||||
at$0.10 on or before 11 August 2023. | |||||||
E. | 5,000,000 | Unquoted | options exercisable | at | |||
$0.15 on or before 11 August 2023 and | |||||||
subject to vesting conditions. | |||||||
F. | 5,000,000 | Unquoted | options exercisable | at | |||
$0.20 on or before 11 August 2023 and | |||||||
subject to vesting conditions. | |||||||
G. | 5,000,000 | Unquoted | options exercisable | at | |||
$0.28 on or before 11 August 2023 and | |||||||
subject to vesting conditions. | |||||||
H. | 5,000,000 | Unquoted | options exercisable | at | |||
$0.30 on or before 11 August 2023 and | |||||||
subject to vesting conditions. | |||||||
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Class | A. | Ordinary shares | ||||
B. | Class A performance rights | |||||
Number acquired | A. | 17,558,328 Ordinary shares | ||||
Number disposed | B. | 17,558,328 Class A performance rights | ||||
Value/Consideration | Pursuant | to | the satisfaction of the Class A | |||
Note: If consideration is non-cash, provide details and estimated | Performance Right milestone as announced on 10 | |||||
valuation | January 2022 estimated value $0.028 per share. | |||||
No. of securities held after change | A. | 23,058,983 ordinary shares | ||||
B. | Nil Class A performance rights | |||||
C. | 17,558,328 Class B performance rights | |||||
D. | 5,000,000 | Unquoted | options exercisable | |||
at$0.10 on or before 11 August 2023. | ||||||
E. | 5,000,000 | Unquoted | options | exercisable | at | |
$0.15 on or before 11 August 2023 and | ||||||
subject to vesting conditions. | ||||||
F. | 5,000,000 | Unquoted | options | exercisable | at | |
$0.20 on or before 11 August 2023 and | ||||||
subject to vesting conditions. | ||||||
G. | 5,000,000 | Unquoted | options | exercisable | at | |
$0.28 on or before 11 August 2023 and | ||||||
subject to vesting conditions. | ||||||
H. | 5,000,000 | Unquoted | options | exercisable | at | |
$0.30 on or before 11 August 2023 and | ||||||
subject to vesting conditions. | ||||||
Nature of change | Conversion of | Class A | Performance Rights | |||
Example: on-market trade, off-market trade, exercise of options, | pursuant | to | the | satisfaction of | the Class | A |
issue of securities under dividend reinvestment plan, participation in | Performance Right milestone as announced on 10 | |||||
buy-back | ||||||
January 2022 | ||||||
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Zelda Therapeutics Ltd. published this content on 04 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 February 2022 06:35:11 UTC.